NewAmsterdam Pharma Company N.V. Ordinary Shares Cash Flow Conversion Efficiency
NewAmsterdam Pharma Company N.V. Ordinary Shares cash flow conversion efficiency. Based on the latest financial reports, NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) has a cash flow conversion efficiency ratio of -0.045x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-32.77 Million) by net assets ($728.07 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of NewAmsterdam Pharma Company N.V. Ordinary Shares (2020–2024)
Cash flow conversion efficiency of NewAmsterdam Pharma Company N.V. Ordinary Shares from 2020 to 2024. This chart illustrates how NewAmsterdam Pharma Company N.V. Ordinary Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data. View NAMS share price today for real-time trading data and today's change.
NewAmsterdam Pharma Company N.V. Ordinary Shares Cash Flow Conversion Ratio Explained
NewAmsterdam Pharma Company N.V. Ordinary Shares cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
NewAmsterdam Pharma Company N.V. Ordinary Shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NewAmsterdam Pharma Company N.V. Ordinary Shares ranked by their cash flow conversion efficiency. Also see how much is NewAmsterdam Pharma Company N.V. Ordinar worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mtar Technologies Limited
NSE:MTARTECH
|
0.048x |
|
Zhejiang Lante Optics Co Ltd
SHG:688127
|
0.080x |
|
Philip Morris CR A.S.
PR:TABAK
|
N/A |
|
Shenzhen Senior Technology Material Co Ltd
SHE:300568
|
0.012x |
|
Insignia Financial Ltd
AU:IFL
|
0.091x |
|
Webull Corp
NASDAQ:BULL
|
0.038x |
|
Shandong Humon Smelting Co Ltd
SHE:002237
|
-0.109x |
|
Chicony Electronics Co Ltd
TW:2385
|
0.018x |
Annual Cash Flow Conversion Efficiency for NewAmsterdam Pharma Company N.V. Ordinary Shares (2020–2024)
The table below shows the annual cash flow conversion efficiency of NewAmsterdam Pharma Company N.V. Ordinary Shares from 2020 to 2024. Review how much free cash does NewAmsterdam Pharma Company N.V. Ordinar generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $757.50 Million | $-158.56 Million | -0.209x | +57.25% |
| 2023-12-31 | $288.39 Million | $-141.22 Million | -0.490x | -2074.60% |
| 2022-12-31 | $430.07 Million | $10.66 Million | 0.025x | +104.76% |
| 2021-12-31 | $56.63 Million | $-29.51 Million | -0.521x | -804.70% |
| 2020-12-31 | $127.46 Million | $-7.34 Million | -0.058x | -- |
About NewAmsterdam Pharma Company N.V. Ordinary Shares
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. Th… Read more